• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Science & Medicine / Cancer / Anal Cancer / Gardasil safe and effective in young men

Gardasil safe and effective in young men

February 11, 2011 By Jonathan 1 Comment

nam aidsmap

Michael Carter
Published: 07 February 2011

The Gardasil vaccine prevents infection and disease associated with high-risk strains of human papilloma virus (HPV) in males, an international team of investigators report in the February 3rd edition of The New England Journal of Medicine.

Sexually experienced boys and young men aged between 16 and 26 were included in the double blind, placebo-controlled study. Among those who received all three doses, the vaccine reduced the risk of lesions associated with high-risk HPV strains (6, 11, 16 and 18) by 90%.

Dr Jane Kim, author of an editorial that accompanied the study, said that its results “affirm the potential for HPV vaccines to prevent related disease in boys and men.”

Infection with human papilloma virus and its associated diseases are common in boys and men. Approximately a quarter of anogenital cancers associated with the infection occur in men, and a disproportionate number of these malignancies occur in gay and other men who have sex with men.

Gardasil has already been shown to prevent persistent infection and disease in girls and women caused by the four strains of human papilloma virus that are associated with a high risk of anogenital cancers. In the US, UK, and many other countries it is recommended that girls receive this or a competitor vaccine before they become sexually active.

To find out about the safety and efficacy of Gardasil in males, investigators designed a study involving 4065 sexually experienced boys and men who were recruited in 18 countries. Each of these individuals reported between one and five lifetime sex partners. They were randomised into two equal groups: one received the vaccine, the other a placebo. These were provided in three doses over a six-month period.

The efficacy of the vaccine at preventing infection with the high-risk strains and disease was examined. Rates of side-effects were also compared between the two groups.

Both heterosexual (3463) and homosexual (602) men were recruited to the study.

Two sets of analyses were performed by the investigators. The first involved all those who were randomised (intent-to-treat); the second was restricted to the 2805 patients who received all three doses of the vaccine or placebo (per protocol).

One month after the administration of the third dose, 97% of those who had received the vaccine had antibodies to all four strains of human papilloma virus.

In the intent-to-treat population, 36 human papilloma virus-related genital lesions occurred in the vaccine group compared to 89 in the placebo arm. This showed that the vaccine had an overall efficacy of 60% at reducing disease.

The vaccine was much more effective in individuals who received all three doses. There were six lesions in the vaccine arm compared to 36 in the placebo arm, an efficacy of 84%.

Read Full Article…

Related

Filed Under: Anal Cancer, Cervical Cancer, Gardasil / Silgard, STD's, Vaccine Marketing, Vaccine Politics/People Tagged With: Autoimmune Diseases, cervarix, Cervical Cancer HPV, Gardasil/Silgard, HPV VACCINES, immunizations, Merck, pharmaceuticals, STD's, vaccinations, Vaccine Adverse Reactions

Trackbacks

  1. Tweets that mention Gardasil safe and effective in young men – SaneVax General Blog -- Topsy.com says:
    February 14, 2011 at 4:45 am

    […] This post was mentioned on Twitter by SaneVax, SaneVax. SaneVax said: https://sanevax.org/blog/?p=2050 […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil Injured Joelle from Australia

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Ashley from Colorado. HPV Vaccine Story

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in